Quick Answer
Boundless Bio, Inc. reported Cash and Equivalents of $17.87 million for fiscal year 2025.
Boundless Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $17.87M | -32.8% |
| 2024 | $26.59M | +12.2% |
| 2023 | $23.71M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.98M | -62.7% | +1.9% |
| June 30, 2025 | $14.70M | -53.1% | -2.8% |
| March 31, 2025 | $15.12M | -39.9% | -43.1% |
| December 31, 2024 | $26.59M | +12.2% | -33.9% |
| September 30, 2024 | $40.21M | +91.8% | +28.2% |
| June 30, 2024 | $31.36M | -24.1% | +24.7% |
| March 31, 2024 | $25.14M | +19.4% | +6.1% |
| December 31, 2023 | $23.71M | — | +13.1% |
- Boundless Bio, Inc. showed a decrease of -32.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Boundless Bio, Inc.’s cash and equivalents has declined by 24.6% (from $23.71 million to $17.87 million).
- The most recent figure is from Boundless Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: